Results 1 - 10 of 33 : 1 2 3 4 Next
Too Much Punishment for Amylin
Several more pancreatitis cases cause investors to panic.
Anemic Amylin's Signs of Recovery
The growth of its main drug is headed in the right direction.
GLP-1 drugs come full circle.
Let the companies do the hard work of telling you when they're going to grow.
These companies are buying back their shares. Should you buy them, too?
Amylin's Down and Up on Diabetes
So exactly why did it drop and then come back up?
A potential blockbuster compound excels in late-stage head-to-head testing.
Maybe what glitters really is gold.
The AIR's Knocked Out of Alkermes
Alkermes initiates a round of cost-cutting.
2008 Should Make or Break MannKind
MannKind updates investors on what to expect this year.